amdiglurax

Amdiglurax is a first-in-class investigational small-molecule neurogenic and neurotrophic modulator being developed primarily for mood and stress-related disorders, including major depressive disorder, bipolar depression, and post-traumatic stress disorder.[1][4] Discovered via an in vitro neurogenesis screen, it enhances hippocampal neuroplasticity and neurogenesis in preclinical models, increases hippocampal volume in rodents, and exerts antidepressant and procognitive effects in animal studies.[1][4][11] Although its precise molecular target is unknown, amdiglurax indirectly enhances brain-derived neurotrophic factor (BDNF) signaling, increases signaling through the TrkB pathway, and upregulates other trophic factors such as glial cell line-derived neurotrophic factor (GDNF), vascular endothelial growth factor (VEGF), and Skp, Cullin, F-box (SCF) in vitro.[1][4] In clinical trials, amdiglurax has shown mixed antidepressant efficacy but reproducible improvements in cognition and memory in patients with major depressive disorder, with current development focusing on biomarker-enriched subpopulations.[1][4] It is administered orally, reaches peak plasma levels within 1–2 hours, exhibits linear pharmacokinetics across typical dosing ranges, and has an elimination half-life of approximately 17–21 hours.[1][4]

Other names

NSI-189 phosphateNSI189 phosphateNSI 189 phosphate